TUKYSA 50 mg film-coated tablets clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2-positive non-resectable locally advanced or metastatic breast cancer “TrasTUCAN Study”
This study is testing a new combination of medicines, Trastuzumab, Tucatinib, and Vinorelbine, for people with HER2-positive breast cancer that has spread or cannot be removed. Researchers want to see how well it shrinks cancer and if it's safe.
For: Non-resectable locally advanced or metastatic HER2-positive breast cancerSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
C4251003- A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations.
This study is looking at a new combination of medicines for people with certain advanced cancers where previous treatments haven't worked well. It aims to see how many people respond to the treatment.
For: Previously Treated · Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 AlterationsGermany · Belgium · Spain - AuthorisedTherapeutic exploratory (Phase II)
"H3RAKLES": Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer
This study, called 'H3RAKLES', is testing new ways to treat a specific type of advanced breast cancer. It combines two medicines, Tucatinib and Trastuzumab, for patients whose cancer has a particular gene change (HER3-mutant) and is not HER2-amplified. We want to see how well this combination works.
For: HER3-mutant and HER2-not amplified metastatic breast cancerFrance